Sort   by:  
 Page size 
UnknownFolding mechanisms steer the amyloid fibril formation propensity of highly homologous proteins.
Not available
S-EPMC5933289 | biostudies-literature
UnknownTumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
Not available
S-EPMC12480687 | biostudies-literature
UnknownSpatial predictors of immunotherapy response in triple-negative breast cancer.
Not available
S-EPMC10533410 | biostudies-literature
UnknownThe Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Not available
S-EPMC11528202 | biostudies-literature
UnknownDevelopment and validation of a gene expression-based Breast Cancer Purity Score.
Not available
S-EPMC11502849 | biostudies-literature
UnknownBreast cancer "tailored follow-up" in Italian oncology units: a web-based survey.
Not available
S-EPMC3979748 | biostudies-literature
UnknownCommunication and visiting policies in Italian intensive care units during the first COVID-19 pandemic wave and lockdown: a nationwide survey.
Not available
S-EPMC9203262 | biostudies-literature
UnknownNeoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Not available
S-EPMC11512588 | biostudies-literature
UnknownTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Not available
S-EPMC6193457 | biostudies-literature
UnknownEffect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
Not available
S-EPMC8492020 | biostudies-literature
Sort   by:  
 Page size